Platform comparison for evaluation of ALK protein immunohistochemical expression, genomic copy number and hotspot mutation status in neuroblastomas.
ALK is an established causative oncogenic driver in neuroblastoma, and is likely to emerge as a routine biomarker in neuroblastoma diagnostics. At present, the optimal strategy for clinical diagnostic evaluation of ALK protein, genomic and hotspot mutation status is not well-studied. We evaluated AL...
Main Authors: | Benedict Yan, Chik Hong Kuick, Malcolm Lim, Kavita Venkataraman, Chandana Tennakoon, Eva Loh, Derrick Lian, May Ying Leong, Manikandan Lakshmanan, Vinay Tergaonkar, Wing-Kin Sung, Shui Yen Soh, Kenneth T E Chang |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4154751?pdf=render |
Similar Items
-
ALK in Neuroblastoma: Biological and Therapeutic Implications
by: Ricky M. Trigg, et al.
Published: (2018-04-01) -
ALK upregulates POSTN and WNT signaling to drive neuroblastoma
by: Miller Huang, et al.
Published: (2024-03-01) -
Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma
by: Pacenta HL, et al.
Published: (2018-10-01) -
5′ ALK Amplification in Neuroblastoma: A Case Report
by: Sara Akhavanfard, et al.
Published: (2021-03-01) -
The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN
by: J. Guan, et al.
Published: (2016-09-01)